Probiotic Supplement for Forever Chemicals Exposure

(AFCRO202 Trial)

This trial aims to determine if a probiotic supplement, specifically Streptococcus salivarius 46-SL1, can reduce PFAS levels in the blood of male firefighters exposed to these chemicals on the job. PFAS, often called "forever chemicals," persist in the body and may impact health. Participants will take either the probiotic or a placebo (a capsule that looks identical but contains no active ingredient) for 12 weeks, then switch to the other option after a break. Male firefighters with a history of PFAS exposure and a specific PFOS level may be suitable for this study. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research on reducing harmful chemical exposure.

Without specific data on Streptococcus salivarius 46-SL1, considering the broader context is beneficial. Probiotics, such as Streptococcus salivarius, are generally well-tolerated by most individuals and are often included in dietary supplements to support gut health. Although the specific strain 46-SL1 is under investigation, probiotics typically have a strong safety record. Side effects, if any, are usually mild, such as stomach upset or gas. The trial's unspecified phase suggests that researchers are still exploring the treatment's safety, making monitoring during the study crucial to ensure safety.¹²³⁴⁵

Unlike traditional treatments for exposure to "forever chemicals," which primarily involve avoidance and detoxification strategies, the probiotic supplement Streptococcus salivarius 46-SL1 offers a novel approach by potentially supporting the body's natural microbiome to mitigate the effects. This treatment is unique because it uses a specific strain of probiotic bacteria that may help reduce the body's absorption of these persistent chemicals. Researchers are excited about this treatment as it represents a shift from reactive to proactive management, possibly providing a more natural and holistic option to combat the long-term health effects of these environmental pollutants.

This trial will evaluate the effects of Streptococcus salivarius 46-SL1, a beneficial bacterium, on reducing PFAS levels in the body. Known as "forever chemicals," PFAS do not break down easily and are linked to health issues such as cancer and hormone problems. Participants will receive the probiotic dietary supplement in one sequence and a placebo in another. Early studies suggest that these probiotics might bind to PFAS in the gut, aiding their removal from the body. Although research on Streptococcus salivarius and PFAS continues, this approach shows promise for mitigating PFAS exposure effects. This could be particularly beneficial for individuals with high occupational exposure, such as firefighters.⁶⁷⁸⁹¹⁰